Since 1992, IL-2 has received FDA approval under names like Aldesleukin for melanoma and kidney cancer treatment. Yet, traditional methods involve high doses of IL-2 injected intravenously, causing ...
Researchers at Peking Union Medical College Hospital have mapped out why pairing two well-known cancer drugs can turn “sleepy” immune cells back into tumor killers. In a new Perspective published ...
- 40% of efficacy-evaluable patients (2 out of 5) in the initial cohort of patients with anti-PD-1 refractory melanoma treated with TransCon IL-2 β/γ in combination with TransCon TLR7/8 Agonist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results